Abstract
Gene expression profiling provides a detailed molecular snapshot of cellular phenotypes that can be used to compare different biological conditions. Nanopore sequencing technology can generate high-resolution transcriptomic data in real-time and at low cost, which heralds new opportunities for molecular medicine. In this study, we demonstrate the clinical utility of real-time transcriptomic profiling by processing RNA sequencing data from childhood acute lymphoblastic leukemia (ALL) patients on-the-fly with a trained neural network classifier. This strategy successfully distinguished 11/12 representative ALL molecular subtypes and one non-leukemia control in as little as 5 minutes of sequencing on a MinION sequencer or in less than 1 hour on disposable, low cost Flongle flow cells. Our findings suggest that real-time transcriptomics constitutes a drastically efficient solution for the molecular diagnosis of ALL and other diseases, where conventional clinical workflows require days if not weeks to achieve similar results.
Competing Interest Statement
MAS, MS and BP have received financial travel support from Oxford Nanopore Technologies.
Funding Statement
This work was partially funded by a Cole Foundation transition award, a Canadian Foundation for Innovation John R. Evans Leaders Fund (40767) and a National Science and Engineering Research Council of Canada Discovery Grant (RGPIN-2022-04265) to MAS. MS is partially supported by a Cole Foundation fellowship. BP is partially supported by a Fonds de Recherche du Quebec - Sante postdoctoral fellowship. MAS is partially supported by a Fonds de Recherche du Quebec - Sante, Junior 1 fellowship and establishment award (307539). We would also like to thank participating patients and their families, as well as the Fondation CHU Sainte-Justine for their global support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Centre Hospitalier Universitaire Sainte-Justine Institutional Review Board (FWA00021692, designated by the Ministere de la Sante et des Services Sociaux du Quebec) gave ethical approval for this work (research protocol project code MP-21-2019-2032).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.